Renal Cell Carcinoma News
One type thermal ablation appeared superior for cT1 a renal cell carcinoma patients.
Investigators observed no differences in surgery time, blood loss, and hospital stay, with deferred vs upfront cytoreductive nephrectomy.
In a population-based study, PN was associated with improved cancer-specific survival by 56%.
In a meta-analysis, partial and radical nephrectomy were associated with similar long-term overall survival, but cancer-specific survival was better with radical nephrectomy.
Outside of clinical trials, targeted therapies for advanced renal cell carcinoma in Medicare patients are associated with modest survival advantages over non-targeted therapies.
The data suggest that OS may actually be worse for patients receiving pazopanib following surgery for metastatic RCC.
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
Nivolumab plus ipilimumab, both checkpoint inhibitors, exhibit promising anti-tumor activity in patients with advanced renal cell carcinoma with brain metastases, researchers report.
Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.
The identification of biomarkers of response and resistance to immune checkpoint inhibitors remains an active area of research.
In this study, more than 40% of patients with metastatic RCC showed signs of hypothyroidism following 2 weeks of treatment with sunitinib.
No overall survival benefit has yet been seen with the regimen in RCC.
Researchers report long-term follow-up results showing no significant difference in oncologic outcomes among partial nephrectomy, radiofrequency ablation, and cryoablation for cT1 renal tumors.
The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Elevated C-reactive protein levels prior to nephrectomy for renal cell carcinoma is associated with an increased risk of renal impairment, a study found.
In a study, left-sided renal cell carcinoma (RCC) was associated with a 15% to 20% increased risk of dying from the malignancy compared with right-sided RCC.
FDA approved pembrolizumab, a PD-1 inhibitor, in combination with axitinib, a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma.
Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.
About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.
New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.